title: [Current treatment concepts for castration resistant prostate cancer].
abstract: Metastasized castration-resistant prostate cancer (mCRPC) is defined by disease progression despite androgen depletion therapy (ADT). While until recently a life-prolonging effect could only be demonstrated for the taxane docetaxel, various alternative therapeutic options based on different mechanisms of action are available today: CYP17-inhibitor abiraterone and antiandrogen enzalutamide target the androgen receptor-signaling pathway, which maintains a crucial role in mCRPC. Cabazitxel - a semisynthetic taxane derivate - is the only second line chemotherapy, which results in a prolongation of overall survival to date. Alpha emitter Radium-223 has the ability to mimic calcium and target bone metastases. Thus, it is a reasonable therapeutic alternative for patients suffering from symptomatic bone metastases. In 2013, Sipuleucel-T was the first immunotherapy approved for CRPC in Europe. In this review we introduce the different therapeutic options to the reader, reflect the possible therapeutic sequences and give a perspective on novel pipeline medications.
authors.affiliation: Klinik für Onkologie, Hämatologie und Knochenmarkstransplantation mit Sektion Pneumologie, Onkologisches Zentrum, Universitätsklinikum Hamburg-Eppendorf.
authors.forename: G
authors.initials: G
authors.lastname: von Amsberg
authors.affiliation: Martini-Klinik am UKE GmbH, Universitätsklinikum Hamburg-Eppendorf.
authors.forename: P
authors.initials: P
authors.lastname: Stroelin
authors.affiliation: Klinik für Onkologie, Hämatologie und Knochenmarkstransplantation mit Sektion Pneumologie, Onkologisches Zentrum, Universitätsklinikum Hamburg-Eppendorf.
authors.forename: C
authors.initials: C
authors.lastname: Bokemeyer
authors.affiliation: Martini-Klinik am UKE GmbH, Universitätsklinikum Hamburg-Eppendorf.
authors.forename: T
authors.initials: T
authors.lastname: Steuber
mesh_terms: D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D001918:Brachytherapy / Q000379:methods*; D003131:Combined Modality Therapy; D000077143:Docetaxel; D019317:Evidence-Based Medicine; D006801:Humans; D008297:Male; D058990:Molecular Targeted Therapy / Q000379:methods*; D064129:Prostatic Neoplasms, Castration-Resistant / Q000628:therapy*; D043823:Taxoids / Q000627:therapeutic use*
chemical_list: D000911:Antibodies, Monoclonal; D000970:Antineoplastic Agents; D043823:Taxoids; D000077143:Docetaxel